MedTrace Logo

Synthetic Genistein (BONISTEIN™) in Patients Who Are Undergoing Surgery for Prostate Cancer

NCT00546039 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2008-09-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate safety and mechanisms of possible chemopreventive effects of synthetic genistein (BONISTEIN™) in patients with localized prostate cancer undergoing laparoscopic radical prostatectomy.

Conditions

  • Prostatic Neoplasms

Interventions

DRUG

Genistein

Capsule, 30 mg, oral daily for 3 to 6 weeks

DRUG

Placebo

Capsule

Sponsors & Collaborators

  • University Hospital, Aker

    lead OTHER

Principal Investigators

  • Steinar J Karlsen, MD, PhD · Aker University Hospital, Oslo Urological Universityclinic

  • Bato Lazarevic, MD · Aker University Hospital, Oslo Urological Universityclinic

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2008-08-31
Completion
2009-01-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00546039 on ClinicalTrials.gov